BRPI0609401A8 - método para tratar ou prevenir inflamação sistêmica em bebês alimentados com fórmula. - Google Patents

método para tratar ou prevenir inflamação sistêmica em bebês alimentados com fórmula.

Info

Publication number
BRPI0609401A8
BRPI0609401A8 BRPI0609401A BRPI0609401A BRPI0609401A8 BR PI0609401 A8 BRPI0609401 A8 BR PI0609401A8 BR PI0609401 A BRPI0609401 A BR PI0609401A BR PI0609401 A BRPI0609401 A BR PI0609401A BR PI0609401 A8 BRPI0609401 A8 BR PI0609401A8
Authority
BR
Brazil
Prior art keywords
treating
systemic inflammation
formula
preventing systemic
fed babies
Prior art date
Application number
BRPI0609401A
Other languages
English (en)
Inventor
Neu Josef
j mcmahon Robert
Herz Udo
Original Assignee
Bristol Myers Squibb Co
Mead Johnson Nutrition Co
Mjn Us Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Mead Johnson Nutrition Co, Mjn Us Holdings Llc filed Critical Bristol Myers Squibb Co
Publication of BRPI0609401A2 publication Critical patent/BRPI0609401A2/pt
Publication of BRPI0609401A8 publication Critical patent/BRPI0609401A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

método para tratar ou prevenir inflamação sistêmica em bebês alimentados com fórmula bem como composição e combinação. a presente invenção refere-se a um novo método para tratar ou prevenir inflamação sistêmica em um bebê alimentado com fórmula. o método administrando ao bebê uma quantidade terapeuticamente eficaz de lgg em combinação com no mínimo um lcpufa.
BRPI0609401A 2005-04-15 2006-03-22 método para tratar ou prevenir inflamação sistêmica em bebês alimentados com fórmula. BRPI0609401A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/106,794 2005-04-15
US11/106,794 US20060233762A1 (en) 2005-04-15 2005-04-15 Method for treating or preventing systemic inflammation in formula-fed infants
PCT/US2006/010415 WO2006113034A1 (en) 2005-04-15 2006-03-22 Use of lactobacillus rhamnosus gg in combination with a long chain polyunsaturated fatty acid for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant

Publications (2)

Publication Number Publication Date
BRPI0609401A2 BRPI0609401A2 (pt) 2010-03-30
BRPI0609401A8 true BRPI0609401A8 (pt) 2018-03-13

Family

ID=36658778

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0609401A BRPI0609401A8 (pt) 2005-04-15 2006-03-22 método para tratar ou prevenir inflamação sistêmica em bebês alimentados com fórmula.

Country Status (13)

Country Link
US (2) US20060233762A1 (pt)
EP (1) EP1868596B1 (pt)
KR (1) KR101277050B1 (pt)
CN (1) CN101146525A (pt)
BR (1) BRPI0609401A8 (pt)
CA (1) CA2599618C (pt)
ES (1) ES2738006T3 (pt)
MX (1) MX2007010804A (pt)
MY (1) MY172984A (pt)
NO (1) NO20074062L (pt)
RU (1) RU2416401C2 (pt)
TW (1) TWI372058B (pt)
WO (1) WO2006113034A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572474B2 (en) * 2005-06-01 2009-08-11 Mead Johnson Nutrition Company Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants
US20090258823A1 (en) * 2006-12-08 2009-10-15 George Caroline L S Composition and methods for the prevention and treatment of gastrointestinal infections
MX2009008875A (es) * 2007-02-28 2009-08-28 Mead Johnson Nutrition Co Producto que contiene probiotico inactivado para niños o infantes.
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
WO2009058799A1 (en) * 2007-11-01 2009-05-07 Wake Forest University School Of Medicine Compositions and methods for prevention and treatment of mammalian diseases
US9439885B2 (en) * 2008-06-03 2016-09-13 Mead Johnson Nutrition Company Method for inhibiting the growth of bacteria
US8498729B2 (en) 2008-08-29 2013-07-30 Smp Logic Systems Llc Manufacturing execution system for use in manufacturing baby formula
CN102985105B (zh) * 2010-01-19 2016-03-09 雅培制药有限公司 包含合生元的营养配方
US10590180B2 (en) * 2015-06-19 2020-03-17 National University Corporation Shizuoka University Immune function development promoter and growth promoter
CN108715822B (zh) * 2018-06-13 2021-09-03 吉林省农业科学院 一株鼠李糖乳杆菌及其在制备抗抑郁产品中的应用
CN121153868A (zh) * 2025-11-21 2025-12-19 四平君乐宝乳业有限公司 适用于食物蛋白过敏婴儿的特殊医学用途配方食品组合物用于改善嗜酸性粒细胞性食管炎的非治疗目的的用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839281A (en) * 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
US5840318A (en) * 1993-05-11 1998-11-24 Immunom Technologies, Inc. Methods and compositions for modulating immune systems of animals
FI104465B (fi) * 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
JPH092959A (ja) * 1995-06-16 1997-01-07 Yakult Honsha Co Ltd ＩｇＥ抗体産生抑制剤および抗アレルギー剤
HUP0300236A3 (en) * 1997-02-21 2003-09-29 Univ Tennessee Res Corp Knoxvi Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis and process for their preparation
US6203797B1 (en) * 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
CA2351469A1 (en) * 1998-12-15 2000-06-22 Susan Marie Kaup Method and composition for the maintenance and restitution of gut integrity
US6696057B1 (en) * 1999-09-22 2004-02-24 Lacpro Industries, Inc. Composition and method for treatment of gastrointestinal disorders and hyperlipidemia
US20030203839A1 (en) * 1999-10-29 2003-10-30 Kruzel Marian L. Immune enhancing composition containing lactoferrin
US20010047036A1 (en) * 1999-12-17 2001-11-29 Vanderhoof Jon A. Composition for improving the proliferative response during adaptation of the gastrointestinal tract and use in short bowel syndrome
US6613549B2 (en) * 2000-02-10 2003-09-02 Urex Biotech, Inc. Probiotic therapy for newborns
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
EP1296693A4 (en) * 2000-06-19 2005-05-25 Mucoprotec Pty Ltd IMMUNOTHERAPY AND PROBIOTIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL OR VIRAL INFECTIONS ON MUCOSAL SURFACES
FI110668B (fi) * 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
FI109602B (fi) * 2001-01-25 2002-09-13 Valio Oy Probioottiyhdistelmä
EP1239032A1 (en) * 2001-03-02 2002-09-11 Société des Produits Nestlé S.A. Lactic acid bacteria as agents for treating and preventing allergy
JP3853673B2 (ja) * 2001-03-09 2006-12-06 森永乳業株式会社 Ｃ型慢性肝炎治療剤
EP1364586A1 (en) * 2002-05-24 2003-11-26 Nestec S.A. Probiotics and oral tolerance
PT1638414E (pt) * 2003-06-23 2009-07-13 Nestec Sa Fórmula para lactentes ou fórmula de transição
US7862808B2 (en) * 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12

Also Published As

Publication number Publication date
ES2738006T3 (es) 2020-01-17
CA2599618A1 (en) 2006-10-26
KR20080025660A (ko) 2008-03-21
CN101146525A (zh) 2008-03-19
NO20074062L (no) 2007-11-13
CA2599618C (en) 2015-04-28
KR101277050B1 (ko) 2013-06-25
US20070009495A1 (en) 2007-01-11
BRPI0609401A2 (pt) 2010-03-30
TW200716146A (en) 2007-05-01
TWI372058B (en) 2012-09-11
RU2007133444A (ru) 2009-05-20
RU2416401C2 (ru) 2011-04-20
US20060233762A1 (en) 2006-10-19
MY172984A (en) 2019-12-17
EP1868596B1 (en) 2019-05-15
WO2006113034A1 (en) 2006-10-26
MX2007010804A (es) 2007-09-26
EP1868596A1 (en) 2007-12-26

Similar Documents

Publication Publication Date Title
CR10192A (es) Compuestos de amido y su uso como productos farmaceuticos
BR112013020620A2 (pt) análogos de ácido 4-hidroxibutírico
MY180558A (en) Pyridin-2-yl-amino-1,2,4- theiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
WO2008054208A3 (en) Use of nutritional compositions for preventing disorders
CO6341636A2 (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
BRPI0915064B8 (pt) derivados de quinoxalinadiona, seus usos, e medicamentos
PH12013500808A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
UA100384C2 (en) Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
NO20056010L (no) Biaryloksymetylaren-karboksylsyrer
BR112012002553A8 (pt) Composição de proteção solar terapêutica e seus usos
BR112012031873A2 (pt) antagonistas de ciclo-hexil-azetidinila do ccr2
TW200633992A (en) Biaryloxymethylarenecarboxylic acids
MX2010001847A (es) Derivados de n-bencil, n'-arilcarbonilpiperazina en la forma de moduladores lxr.
WO2007010281A3 (en) Use of thiazole derivatives and analogues in disorders caused by free fatty acids
NO20092018L (no) Fremgangsmater for a behandle depresjon
TW200716146A (en) Method for treating or preventing systemic inflammation in formula-fed infants
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
BRPI0519854A2 (pt) 4- feniltetraidroquinolinas substituìdas, métodos para produzì-las, seu uso como fármaco, e fármaco contendo-as
BRPI0608328A2 (pt) uso de lactobacillus rhamnosus gg para tratamento, prevenção ou redução de inflamação sistêmica em um bebê alimentado com fórmula
WO2007095609A3 (en) Use of benzo-heteroaryl sulfamide derivatives for the treatment of mania and bipolar disorder
BR112012031470A2 (pt) antagonistas de ciclo-hexil-azetidinila de ccr2
EA201290485A1 (ru) Производные бензамида
ATE407126T1 (de) Herstellung von (s)-4-fluormethyl-dihydro-furan-2-on
MX2013011561A (es) Compuestos de benzodioxepina y benzodioxina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MEAD JOHNSON NUTRITION COMPANY (US)

Free format text: TRANSFERIDO DE: BRISTOL-MYERS SQUIBB COMPANY

B25A Requested transfer of rights approved

Owner name: MJN U.S. HOLDINGS LLC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL